@article{oai:niigata-u.repo.nii.ac.jp:00020876, author = {水戸, 將郎}, issue = {7}, journal = {新潟医学会雑誌, 新潟医学会雑誌}, month = {Jul}, note = {DDAVP infusion shortens the bleeding time in patients with some types of platelet dysfunction and may be useful for hemostatic control. In order to clarify the mechanism of DDAVP to correct or bypass the defects, the effect was examined in 14 patients with prolonged bleeding time, i.e, 12 with various kinds of platelet dysfunction, 1 with chronic myelogenous leukemia (CML), and in an aspirin-ingested volunteer. DDAVP shortened the bleeding time in 9 patients with platelet dysfunctions;abnormal cyclooxygenase, aspirin induced defect, or the decreased response to thromboxane A_2, but did not in 5 patients with A23187-abnormality, thrombasthenia, Hermansky-Pudlak syndrome or defect associated with myelogenous leukemia, DDAVP caused no improvement in either the reduced aggregability or the reduced retention rate, and no signs of in vitro activation in the platelet shape in all patients examined. The RCof was elevated similarly in DDAVP-effective patients and DDAVP-noneffective patients. These date suggest that DDAVP improves the hemostasis through primary aggregation, normal intracellular Ca^<2+> mobilization and release of dense bodies, and not directly through either an increase of RCof, general activation of circulating platelets or thromboxane A_2-related pathway.}, pages = {660--670}, title = {DDAVPによる血小板(機能)異常症の出血管理とその機序}, volume = {106}, year = {1992} }